![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1671882
¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°, ¿¡ÀÌÀüÆ®º°, ¿¬·Éº°, À¯Åë ä³Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°Malaria Vaccines Market, By Vaccine Type, By Agent, By Age, By Distribution Channel, By End Users, By Geography |
¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀº 2025³â¿¡ 6¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 14¾ï 3,270¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025-2032³â ¿¬Æò±Õ 12.7% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
º¸°í ¹üÀ§ | º¸°í¼ »ó¼¼ ³»¿ë | ||
---|---|---|---|
±âÁØ¿¬µµ | 2024³â | 2025³â ½ÃÀå ±Ô¸ð | 6¾ï 2,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR: | 12.70% | 2032³â °¡Ä¡ ¿¹Ãø | 14¾ï 3,270¸¸ ´Þ·¯ |
¸»¶ó¸®¾Æ´Â °¨¿°µÈ Aedes aegypti ¸ð±â¿¡ ¹°·Á »ç¶÷¿¡°Ô °¨¿°µÇ´Â ±â»ýÃæ¿¡ ÀÇÇØ À¯¹ßµÇ´Â »ý¸íÀ» À§ÇùÇÏ´Â Áúº´ÀÔ´Ï´Ù. »ìÃæÁ¦ ó¸®µÈ ¸ð±âÀå, »ìÃæÁ¦ »ìÆ÷, Ç׸»¶ó¸®¾Æ ¾àǰ µî ÇöÀç »ç¿ë °¡´ÉÇÑ ¸»¶ó¸®¾Æ ¿¹¹æ ¹× °ü¸® Àü·«Àº ¸»¶ó¸®¾ÆÀÇ È®»êÀ» ¾ïÁ¦Çϱ⿡ ºÒÃæºÐÇÑ °ÍÀ¸·Î ¹àÇôÁ³½À´Ï´Ù. µû¶ó¼ ¸»¶ó¸®¾Æ ¹é½ÅÀº ¸»¶ó¸®¾Æ°¡ À¯ÇàÇÏ´Â Áö¿ª¿¡¼ ¸»¶ó¸®¾ÆÀÇ ÀÌȯÀ²°ú »ç¸Á·üÀ» ³·Ãß±â À§ÇÑ ±ä±ÞÇϰí ÇʼöÀûÀÎ °øÁߺ¸°Ç ¼ö´ÜÀ¸·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù. ¹é½ÅÀº ´ë±Ô¸ð ÀÇ·á ÀÎÇÁ¶ó ¾øÀ̵µ Àå±â°£ Áö¼ÓµÇ´Â ¸é¿ª·ÂÀ» Á¦°øÇÒ ¼ö ÀÖÀ¸¹Ç·Î ¸»¶ó¸®¾Æ ÅðÄ¡ ¸ñÇ¥¸¦ ´Þ¼ºÇÒ ¼ö ÀÖ´Â ºñ¿ë È¿À²ÀûÀ̰í Áö¼Ó°¡´ÉÇÑ ¼Ö·ç¼ÇÀ» Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù.
¼¼°è ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀº ƯÈ÷ ¾ÆÇÁ¸®Ä« ±¹°¡¸¦ Áß½ÉÀ¸·Î Àü ¼¼°è¿¡¼ ¸»¶ó¸®¾ÆÀÇ Áúº´ ºÎ´ãÀÌ Å©°í, ¼¼°è º¸°Ç ±â°ü¿¡¼ ¸»¶ó¸®¾Æ ¹é½Å °³¹ßÀ» À§ÇØ ¸¹Àº ÀÚ±ÝÀ» Áö¿øÇϰí ÀÖÀ¸¸ç, ¹é½ÅÀÌ Áß¿äÇÑ °øÁߺ¸°Ç °³ÀÔÀ¸·Î ¹Þ¾Æµé¿©Áö°í ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¸»¶ó¸®¾Æ ¿øÃæÀÇ º¹ÀâÇÑ ¼ö¸íÁÖ±â·Î ÀÎÇÑ È¿°úÀûÀÎ ¸»¶ó¸®¾Æ ¹é½Å °³¹ßÀÇ ±â¼úÀû ¾î·Á¿ò°ú ¹æ¾î ¸é¿ª ¹ÝÀÀ¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀÌÇØ ºÎÁ·À¸·Î ÀÎÇØ ½ÃÀå ÀáÀç·ÂÀÌ °è¼Ó ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¹é½ÅÇÐ, ¸é¿ªÇÐ, º´¿øÃ¼ À¯ÀüüÇÐÀÇ ¹ßÀüÀº »õ·Î¿î ¹é½Å ¼³°è Á¢±Ù¹ý°ú Ç׿ø Ç¥Àû °³¹ß ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¼¼°èº¸°Ç±â±¸(WHO), º¸°Ç ºÐ¾ß ÀûÁ¤±â¼ú ÇÁ·Î±×·¥, ¸»¶ó¸®¾Æ ¹é½Å ±¸»ó(PATH MVI), Á¤ºÎ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ µîÀÌ Çù·ÂÇÏ¿© »ý»ê ´É·ÂÀ» È®ÀåÇÏ°í ¸»¶ó¸®¾Æ ¹é½ÅÀ» »óÀç Áý´Ü¿¡ ¼º°øÀûÀ¸·Î º¸±ÞÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼ö ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼´Â ¼¼°èÀÇ ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®Çϰí, 2025³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.
¼¼°è ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ °³¿äÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅ͸¦ ±âÁØÀ¸·Î Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
ÁÖ¿ä ±â¾÷À¸·Î´Â GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., BioNTech SE µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
¸»¶ó¸®¾Æ ¹é½Å ¼¼°è ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è ¸»¶ó¸®¾Æ ¹é½Å ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.
Global Malaria Vaccines Market is estimated to be valued at USD 620.0 Mn in 2025 and is expected to reach USD 1,432.7 Mn by 2032, growing at a compound annual growth rate (CAGR) of 12.7% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 620.0 Mn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 12.70% | 2032 Value Projection: | USD 1,432.7 Mn |
Malaria is a life-threatening disease caused by parasites that are transmitted to people through the bites of infected Anopheles mosquitoes. The currently available strategies for malaria prevention and control such as insecticide treated nets, spraying of insecticides and antimalarial drugs are proving insufficient to curb the spread of the disease. This makes malaria vaccines an urgent and vital public health tool to reduce malaria morbidity and mortality in endemic regions. Vaccines can provide long lasting immunity without requiring large healthcare infrastructure, thereby offering a cost-effective and sustainable solution towards malaria elimination goals.
The global malaria vaccines market is primarily driven by the high disease burden of malaria worldwide, especially in African countries, massive funding for malaria vaccine development from global health organizations and growing acceptance of vaccines as an important public health intervention. However, technical challenges in developing an effective malaria vaccine owing to the complex life cycle of parasite Plasmodium and lack of comprehensive understanding of protective immune responses continue to restrain market potential. Meanwhile, ongoing advancements in vaccinology, immunology, and pathogen genomics have created opportunities for the development of novel vaccine design approaches and antigen targets. Further opportunities lie in expanding manufacturing capacity and ensuring successful uptake of malaria vaccines, once available, in malaria endemic populations through coordinated efforts of World Health Organization (WHO), Program for Appropriate Technology in Health, Malaria Vaccine Initiative (PATH MVI), and government immunization programs.
This report provides in-depth analysis of the global malaria vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2025 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global malaria vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include GlaxoSmithKline plc, Sanaria Inc., Nobelpharma Co., Sumaya Biotech, GenVec, Merck & Co., Inc., Pfizer Inc., Johnson & Johnson, Bharat Biotech, Serum Institute of India, Takeda Pharmaceutical Company, Novavax, Inc., Inovio Pharmaceuticals, Vaxart, Inc., and BioNTech SE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global malaria vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global malaria vaccines market